Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Follow-Up Questions
Psyence Biomedical Ltd (PBM)의 PER은 얼마입니까?
Psyence Biomedical Ltd의 PER은 2.6223입니다
Psyence Biomedical Ltd의 CEO는 누구입니까?
Mr. Marc Balkin은 2021부터 회사에 합류한 Psyence Biomedical Ltd의 Chief Executive Officer입니다.
PBM 주식의 가격 성능은 어떻습니까?
PBM의 현재 가격은 $4.94이며, 전 거래일에 decreased 6.78% 하였습니다.
Psyence Biomedical Ltd의 주요 사업 주제나 업종은 무엇입니까?
Psyence Biomedical Ltd은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
